Author

S. Wilkinson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Organism:mouse· 2 Approach:statistical model· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:clustering· 1

Frequent Co-Authors

A. G. Sowalsky· 4 shared A. T. Ku· 2 shared A. A. Germanos· 1 shared A. A. Hamid· 1 shared A. C. Hsieh· 1 shared A. H. Sims· 1 shared A. Long· 1 shared A. M. Bergman· 1 shared

Activity by Year

2019-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. G. Sowalsky

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Loss of tristetraprolin activates NF-κB induced phenotypic plasticity and primes transition to lethal prostate cancer

K. L. Morel, A. A. Hamid, B. G. Falcon, J. N. Singh, S. Linder, A. M. Bergman, H. G. van der Poel, I. Hofland, E. M. Bekers, S. Trostel, S. Wilkinson, A. T. Ku, D. L. Burkhart, M. Kim, J. Kim, , L. Ellis

This study shows that loss of ZFP36 promotes NF-κB activation and phenotypic plasticity in prostate cancer, leading to aggressive disease and castration resistance, which can be reversed by NF-κB inhibition.

bioRxiv · Aug 5, 2022 · PreprintCancer Biology

Prediction of cancer treatment response from histopathology images through imputed transcriptomics

D.-T. Hoang, G. Dinstag, L. C. Hermida, D. S. Ben-Zvi, E. Elis, K. Caley, S.-J. Sammut, S. Sinha, N. Sinha, C. H. Dampier, C. Stossel, T. Patil, A. Rajan, W. Lassoued, J. Strauss, , E. Ruppin

ENLIGHT-DeepPT predicts cancer treatment response from H&E slides by first imputing transcriptomics and then using that data to predict response across multiple therapies and cancer types.

bioRxiv · Jun 7, 2022 · PreprintCancer Biology

Defining cellular population dynamics at single cell resolution during prostate cancer progression

A. A. Germanos, S. Arora, Y. Zheng, E. T. Goddard, I. M. Coleman, A. T. Ku, S. Wilkinson, R. A. Amezquita, M. Zager, A. Long, Y. C. Yang, J. H. Bielas, R. Gottardo, C. M. Ghajar, P. S. Nelson, , A. C. Hsieh

This study examines prostate cancer progression at single-cell resolution, identifying castration-resistant luminal cells and their role in treatment resistance and tumor heterogeneity.

bioRxiv · Mar 2, 2022Cancer Biology

Toll-like receptor 2 orchestrates a potent anti-tumor response in non-small cell lung cancer

F. R. Millar, A. Pennycuick, M. Muir, A. Quintanilla, P. Hari, E. Freyer, P. Gautier, A. Meynert, V. H. Teixeira, J. Connelly, W. A. Wallace, A. H. Sims, M. C. Frame, L. Boulter, S. M. Janes, , J. C. Acosta

This study identifies TLR2 as a tumor suppressor in early-stage lung cancer, showing its role in immune surveillance and tumor growth reduction through synthetic agonist administration.

bioRxiv · Jun 4, 2021 · PreprintCancer Biology

MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity

N. C. Whitlock, S. Y. Trostel, S. Wilkinson, N. T. Terrigino, S. T. Hennigan, R. Lake, N. V. Carrabba, R. Atway, E. D. Walton, B. E. Gryder, B. J. Capaldo, H. Ye, A. G. Sowalsky

This study shows that MYC down-regulates MEIS1 in prostate cancer, which increases AR activity and HOXB13 expression, promoting tumor development.

bioRxiv · Nov 20, 2019Cancer Biology